{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:53:36Z","timestamp":1785556416269,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41434-025-00549-2","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:41:23Z","timestamp":1751539283000},"page":"599-609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Systemically delivered lipid nanoparticle-mRNA encoding lysosomal acid \u03b2-glucosidase restores the enzyme deficiency in a murine Gaucher disease model"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7445-8467","authenticated-orcid":false,"given":"Yuanqing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiang","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"549_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12881-019-0759-1","volume":"20","author":"J Sheth","year":"2019","unstructured":"Sheth J, Bhavsar R, Mistri M, Pancholi D, Bavdekar A, Dalal A, et al. Gaucher disease: single gene molecular characterization of one-hundred Indian patients reveals novel variants and the most prevalent mutation. BMC Med Genet. 2019;20:31.","journal-title":"BMC Med Genet"},{"key":"549_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441.","journal-title":"Int J Mol Sci"},{"key":"549_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/path.4751","volume":"239","author":"A Vardi","year":"2016","unstructured":"Vardi A, Zigdon H, Meshcheriakova A, Klein AD, Yaacobi C, Eilam R, et al. Delineating pathological pathways in a chemically induced mouse model of Gaucher disease. J Pathol. 2016;239:496\u2013509.","journal-title":"J Pathol"},{"key":"549_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/humu.20676","volume":"29","author":"KS Hruska","year":"2008","unstructured":"Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29:567\u201383.","journal-title":"Hum Mutat"},{"key":"549_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/path.3021","volume":"226","author":"TM Cox","year":"2012","unstructured":"Cox TM, Cachon-Gonzalez MB. The cellular pathology of lysosomal diseases. J Pathol. 2012;226:241\u201354.","journal-title":"J Pathol"},{"key":"549_CR6","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/stem.1732","volume":"32","author":"LM Panicker","year":"2014","unstructured":"Panicker LM, Miller D, Awad O, Bose V, Lun Y, Park TS, et al. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. Stem Cells. 2014;32:2338\u201349.","journal-title":"Stem Cells"},{"key":"549_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ymgme.2021.12.009","volume":"135","author":"PS Kishnani","year":"2022","unstructured":"Kishnani PS, Al-Hertani W, Balwani M, Goker-Alpan O, Lau HA, Wasserstein M, et al. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. Mol Genet Metab. 2022;135:154\u201362.","journal-title":"Mol Genet Metab"},{"key":"549_CR8","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1517\/14656566.9.11.1987","volume":"9","author":"NJ Weinreb","year":"2008","unstructured":"Weinreb NJ. Imiglucerase and its use for the treatment of Gaucher\u2019s disease. Expert Opin Pharmacother. 2008;9:1987\u20132000.","journal-title":"Expert Opin Pharmacother"},{"key":"549_CR9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ajh.24491","volume":"91","author":"V Murugesan","year":"2016","unstructured":"Murugesan V, Chuang W-L, Liu J, Lischuk A, Kacena K, Lin H, et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016;91:1082\u20139.","journal-title":"Am J Hematol"},{"key":"549_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","volume":"13","author":"SE Gary","year":"2018","unstructured":"Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab. 2018;13:107\u201318.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"549_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ymgme.2012.11.010","volume":"108","author":"TL Yap","year":"2013","unstructured":"Yap TL, Velayati A, Sidransky E, Lee JC. Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab. 2013;108:56\u201364.","journal-title":"Mol Genet Metab"},{"key":"549_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/sctm.18-0259","volume":"8","author":"ZS Badieyan","year":"2019","unstructured":"Badieyan ZS, Evans T. Concise review: application of chemically modified mRNA in cell fate conversion and tissue engineering. Stem Cells Transl Med. 2019;8:833\u201343.","journal-title":"Stem Cells Transl Med"},{"key":"549_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6893","volume":"6","author":"J Nelson","year":"2020","unstructured":"Nelson J, Sorensen EW, Mintri S, Rabideau AE, Zheng W, Besin G, et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci Adv. 2020;6:eaaz6893.","journal-title":"Sci Adv"},{"key":"549_CR14","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","volume":"12","author":"S Vaidyanathan","year":"2018","unstructured":"Vaidyanathan S, Azizian KT, Haque A, Henderson JM, Hendel A, Shore S, et al. Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol Ther Nucleic Acids. 2018;12:530\u201342.","journal-title":"Mol Ther Nucleic Acids"},{"key":"549_CR15","doi-asserted-by":"crossref","unstructured":"Xu S, Yang K, Li R, Zhang L. mRNA vaccine era-mechanisms, drug platform and clinical prospection. Int J Mol Sci. 2020;21:6582.","DOI":"10.3390\/ijms21186582"},{"key":"549_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1089\/hum.2019.090","volume":"30","author":"PGV Martini","year":"2019","unstructured":"Martini PGV, Guey LT. A new era for rare genetic diseases: messenger RNA therapy. Hum Gene Ther. 2019;30:1180\u20139.","journal-title":"Hum Gene Ther"},{"key":"549_CR17","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s12265-013-9494-8","volume":"6","author":"JA Bernal","year":"2013","unstructured":"Bernal JA. RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications. J Cardiovasc Transl Res. 2013;6:956\u201368.","journal-title":"J Cardiovasc Transl Res"},{"key":"549_CR18","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1136\/gutjnl-2019-318269","volume":"68","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, Martini PGV, Avila MA, Fontanellas A. Messenger RNA therapy for rare genetic metabolic diseases. Gut. 2019;68:1323\u201330.","journal-title":"Gut"},{"key":"549_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ebiom.2019.07.003","volume":"45","author":"D An","year":"2019","unstructured":"An D, Frassetto A, Jacquinet E, Eybye M, Milano J, DeAntonis C, et al. Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia. EBioMedicine. 2019;45:519\u201328.","journal-title":"EBioMedicine"},{"key":"549_CR20","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","volume":"118","author":"N Dekker","year":"2011","unstructured":"Dekker N, van Dussen L, Hollak CEM, Overkleeft H, Scheij S, Ghauharali K, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118:e118\u2013e27.","journal-title":"Blood"},{"key":"549_CR21","doi-asserted-by":"publisher","first-page":"e0252325","DOI":"10.1371\/journal.pone.0252325","volume":"16","author":"NK Polinski","year":"2021","unstructured":"Polinski NK, Martinez TN, Gorodinsky A, Gareus R, Sasner M, Herberth M, et al. Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model. PLOS ONE. 2021;16:e0252325.","journal-title":"PLOS ONE"},{"key":"549_CR22","doi-asserted-by":"publisher","first-page":"12101","DOI":"10.1073\/pnas.1108197108","volume":"108","author":"SP Sardi","year":"2011","unstructured":"Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, et al. CNS expression of glucocerebrosidase corrects -synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci USA. 2011;108:12101\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"549_CR23","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","volume":"163","author":"YH Xu","year":"2003","unstructured":"Xu YH, Quinn B, Witte D, Grabowski GA. Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol. 2003;163:2093\u2013101.","journal-title":"Am J Pathol"},{"key":"549_CR24","doi-asserted-by":"publisher","first-page":"e10750","DOI":"10.1371\/journal.pone.0010750","volume":"5","author":"Y-H Xu","year":"2010","unstructured":"Xu Y-H, Sun Y, Barnes S, Grabowski GA, Schiffmann R. Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PloS ONE. 2010;5:e10750.","journal-title":"PloS ONE"},{"key":"549_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8982756","volume":"2018","author":"W Zheng","year":"2018","unstructured":"Zheng W, Du S, Tian M, Xu W, Tian Y, Li T, et al. Lepidium meyenii Walp exhibits anti-inflammatory activity against ConA-induced acute hepatitis. Mediat Inflamm. 2018;2018:8982756.","journal-title":"Mediat Inflamm"},{"key":"549_CR26","doi-asserted-by":"publisher","first-page":"12804","DOI":"10.1074\/jbc.M114.635763","volume":"290","author":"YR Ji","year":"2015","unstructured":"Ji YR, Kim HJ, Bae KB, Lee S, Kim MO, Ryoo ZY. Hepatic serum amyloid A1 aggravates T cell-mediated hepatitis by inducing chemokines via Toll-like receptor 2 in mice. J Biol Chem. 2015;290:12804\u201311.","journal-title":"J Biol Chem"},{"key":"549_CR27","first-page":"3","volume":"61","author":"M de Fost","year":"2003","unstructured":"de Fost M, Aerts JM, Hollak CE. Gaucher disease: from fundamental research to effective therapeutic interventions. Neth J Med. 2003;61:3\u20138.","journal-title":"Neth J Med"},{"key":"549_CR28","first-page":"282","volume":"3","author":"TN Campbell","year":"2004","unstructured":"Campbell TN, Choy FY. Knockdown of chimeric glucocerebrosidase by green fluorescent protein-directed small interfering RNA. Genet Mol Res. 2004;3:282\u20137.","journal-title":"Genet Mol Res"},{"key":"549_CR29","first-page":"299","volume":"4","author":"TM Cox","year":"2010","unstructured":"Cox TM. Gaucher disease: clinical profile and therapeutic developments. Biologics. 2010;4:299\u2013313.","journal-title":"Biologics"},{"key":"549_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1064924","volume":"14","author":"J Kido","year":"2023","unstructured":"Kido J, Sugawara K, Nakamura K. Gene therapy for lysosomal storage diseases: current clinical trial prospects. Front Genet. 2023;14:1064924.","journal-title":"Front Genet"},{"key":"549_CR31","doi-asserted-by":"publisher","DOI":"10.2217\/frd-2022-0019","volume":"3","author":"DA Hughes","year":"2023","unstructured":"Hughes DA, Ferrante F. GALILEO-1: a phase I\/II safety and efficacy study of FLT201 gene therapy for Gaucher Disease Type 1. Future Rare Dis. 2023;3:FRD35.","journal-title":"Future Rare Dis"},{"key":"549_CR32","first-page":"157","volume":"8","author":"DP Rastall","year":"2015","unstructured":"Rastall DP, Amalfitano A. Recent advances in gene therapy for lysosomal storage disorders. Appl Clin Genet. 2015;8:157\u201369.","journal-title":"Appl Clin Genet"},{"key":"549_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.624988","volume":"8","author":"C Sevin","year":"2021","unstructured":"Sevin C, Deiva K. Clinical trials for gene therapy in lysosomal diseases with CNS involvement. Front Mol Biosci. 2021;8:624988.","journal-title":"Front Mol Biosci"},{"key":"549_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/hum.2018.072","volume":"30","author":"S Du","year":"2019","unstructured":"Du S, Ou H, Cui R, Jiang N, Zhang M, Li X, et al. Delivery of glucosylceramidase beta gene using AAV9 vector therapy as a treatment strategy in mouse models of gaucher disease. Hum Gene Ther. 2019;30:155\u201367.","journal-title":"Hum Gene Ther"},{"key":"549_CR35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ymthe.2020.11.020","volume":"29","author":"F Tucci","year":"2021","unstructured":"Tucci F, Scaramuzza S, Aiuti A, Mortellaro A. Update on clinical ex vivo hematopoietic stem cell gene therapy for inherited monogenic diseases. Mol Ther. 2021;29:489\u2013504.","journal-title":"Mol Ther"},{"key":"549_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuron.2019.03.020","volume":"102","author":"E Hudry","year":"2019","unstructured":"Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron. 2019;102:263.","journal-title":"Neuron"},{"key":"549_CR37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.omtm.2020.11.018","volume":"20","author":"M Dahl","year":"2021","unstructured":"Dahl M, Smith EMK, Warsi S, Rothe M, Ferraz MJ, Aerts J, et al. Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector. Mol Ther Methods Clin Dev. 2021;20:312\u201323.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"549_CR38","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.ymgme.2020.12.050","volume":"132","author":"R Corbau","year":"2021","unstructured":"Corbau R, Miranda C, Comper F, Kalcheva P, Chisari E, Cocita C, et al. FLT201: an AAV-mediated gene therapy for type 1 Gaucher disease designed to target difficult to reach tissues. Mol Genet Metab. 2021;132:S28\u2013S9.","journal-title":"Mol Genet Metab"},{"key":"549_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27\u201331.","journal-title":"J Basic Clin Pharm"},{"key":"549_CR40","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s41586-024-07266-7","volume":"628","author":"D Koeberl","year":"2024","unstructured":"Koeberl D, Schulze A, Sondheimer N, Lipshutz GS, Geberhiwot T, Li L, et al. Interim analyses of a first-in-human phase 1\/2 mRNA trial for propionic acidaemia. Nature. 2024;628:872\u20137.","journal-title":"Nature"},{"key":"549_CR41","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1056\/NEJMoa2405734","volume":"392","author":"DM Cohn","year":"2025","unstructured":"Cohn DM, Gurugama P, Magerl M, Katelaris CH, Launay D, Bouillet L, et al. CRISPR-based therapy for hereditary angioedema. N. Engl J Med. 2025;392:458\u201367.","journal-title":"N. Engl J Med"},{"key":"549_CR42","unstructured":"Pharmacoeconomic Review Report: Eliglustat (Cerdelga): (Sanofi Genzyme): Indication: Gaucher Disease Type 1 [Internet]. CADTH Common Drug Reviews. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00549-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00549-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00549-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:38:41Z","timestamp":1766047121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00549-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00549-2","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees of Immorna Biotechnology\/Immorna Biotherapeutics. Z.W., Y. L., and Z. G. are inventors to the Chinese patent CN118903476B.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals and relevant Chinese laws and regulations. All animal use adhered to the IACUC guidelines for animal ethics and welfare. The in vivo experiment protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Shanghai Jiaotong University, China (authorization number: A2022044), and Shanghai Model Organisms Center, Inc., China (authorization number: No. 2020-0047).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}}]}}